A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
about
Clinical relevance of genetic polymorphisms in the human CYP2C subfamilyPhenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals.Pharmacogenetics in Jewish populations.Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian populationEffects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer.Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy.Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.Current State and Future Prospects of Direct-to-Consumer PharmacogeneticsMolecular mechanisms of genetic variation and transcriptional regulation of CYP2C19.A human minor histocompatibility antigen resulting from differential expression due to a gene deletionClinical Application of CYP2C19 Pharmacogenetics Toward More Personalized MedicineInterindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase contentFunctional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort.Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.The role of pharmacogenetics in nonmalignant gastrointestinal diseases.Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications.The Affymetrix DMET Plus platform reveals unique distribution of ADME-related variants in ethnic Arabs.Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients.
P2860
Q28362533-25417B58-93DA-4AC0-B79B-4BE9B0B91D03Q33290485-08521725-6C87-489F-9351-1D4623D900CAQ34458720-6EF75F1D-4239-41A2-B850-E7937E3C564DQ35802629-E0DA40E7-448D-4954-9777-A1982D162F3CQ35826832-BA432FFD-3882-4838-9C30-ED72027E1FBCQ35846595-785059F8-7047-457A-A356-239D1C125098Q35952367-9D93900B-861E-4353-90AB-8EB97354765CQ35972229-45B9271B-223D-436C-8AB6-F49E08E64EEDQ36053279-7253C9C2-A735-430C-B731-B1E88D68C8D1Q36053568-6F6CCC4D-417B-498F-A454-32C7A733312AQ36053911-1B124C2A-650E-4985-8CCC-C98B2B4481EDQ36174824-0880F35C-6402-4614-A2F6-176DE2140E28Q36307008-8CAFFFFE-C6A7-4B86-B2A4-32CD99AD4E43Q36370375-6BFA2736-59E5-43F1-A85A-242C84868F62Q36580034-FCE29019-BE0A-4342-97BB-EEDC800046C0Q36643041-9BA0E59C-ED5B-4CEC-B7DC-F2734CD6996DQ37199426-9FB13A23-A179-4E43-9103-5039E6ADE039Q37538683-8E0717B5-2966-4227-B482-758676879497Q37981892-927DA6FF-8A25-409C-AB71-F685B33DE660Q41595607-62E95959-280D-4042-AE15-3B99BD4A26D0Q42047832-396C8DE6-05A9-4AB6-A7D1-0B53CD71C90CQ42204185-BA1C9FC0-F117-41D0-8897-1B704991C146Q47554139-E8B930A3-5433-436E-9EA5-706EB763206AQ49925445-49FB64BE-C395-4B61-A446-D8C03D6F8108
P2860
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
A new genetic defect in human ...... or metabolism of S-mephenytoin
@ast
A new genetic defect in human ...... or metabolism of S-mephenytoin
@en
A new genetic defect in human ...... or metabolism of S-mephenytoin
@nl
type
label
A new genetic defect in human ...... or metabolism of S-mephenytoin
@ast
A new genetic defect in human ...... or metabolism of S-mephenytoin
@en
A new genetic defect in human ...... or metabolism of S-mephenytoin
@nl
prefLabel
A new genetic defect in human ...... or metabolism of S-mephenytoin
@ast
A new genetic defect in human ...... or metabolism of S-mephenytoin
@en
A new genetic defect in human ...... or metabolism of S-mephenytoin
@nl
P2093
P1476
A new genetic defect in human ...... or metabolism of S-mephenytoin
@en
P2093
C Bouchardy
G R Wilkinson
J A Goldstein
J Blaisdell
J M Wright
R J Ferguson
S Benhamou
S M De Morais
P304
P407
P577
1998-01-01T00:00:00Z